Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

Ivosidenib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-06-2018 | Acute myeloid leukemia | ASCO 2018 | Article

    Ivosidenib gives encouraging results in IDH1-mutated high-risk AML

    Ivosidenib induces durable remission in nearly a third of patients with isocitrate dehydrogenase 1-mutated relapsed or refractory acute myeloid leukemia, phase 1 study data show.

    Published in:
    N Engl J Med 2018; Advance online publication
  2. 30-07-2018 | FDA | News | Article
    approvalsWatch

    Ivosidenib, filgrastim biosimilar receive approvals

    Ivosidenib may be used for adult patients with relapsed or refractory AML who have tested positive for a susceptible IDH1 mutation; an accompanying assay for the mutation has also been approved.

  3. 19-07-2018 | Acute myeloid leukemia | Article

    Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

    DiNardo CD et al. N Engl J Med  2018; 378(25): 2386-2398. doi:10.1056/NEJMoa1716984

  4. 31-10-2017 | Acute myeloid leukemia | Article

    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

    This article summarizes the role of isocitrate dehydrogenase (IDH)-1 and IDH2 mutations in leukemogenesis, and covers recent clinical trials evaluating the effect of direct inhibition of IDH1 and IDH2. Nassereddine S, Lap CJ, Haroun F et al. Ann Hematol 2017; 96:1983. doi:10.1007/s00277-017-3161-0

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.